Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO TherapiesGlobeNewsWire • 01/04/23
Amid criticism for its handling of another Alzheimer's drug, FDA will decide this week whether to approve lecanemabMarket Watch • 01/03/23
Congressional report: U.S. FDA broke own protocols in approving Biogen Alzheimer's drugReuters • 12/29/22
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 CollaborationGlobeNewsWire • 12/19/22
Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, LecanemabPRNewsWire • 12/12/22
FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)GlobeNewsWire • 12/09/22